Fmr LLC Buys 9,259 Shares of Harrow, Inc. (NASDAQ:HROW)

Fmr LLC raised its stake in Harrow, Inc. (NASDAQ:HROW) by 521.6% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 11,034 shares of the company’s stock after purchasing an additional 9,259 shares during the quarter. Fmr LLC’s holdings in Harrow were worth $496,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently made changes to their positions in the company. Mirae Asset Global Investments Co. Ltd. raised its holdings in Harrow by 21.5% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,283 shares of the company’s stock valued at $57,000 after buying an additional 227 shares during the last quarter. The Manufacturers Life Insurance Company increased its position in shares of Harrow by 5.0% in the second quarter. The Manufacturers Life Insurance Company now owns 11,865 shares of the company’s stock valued at $248,000 after acquiring an additional 567 shares during the period. Quest Partners LLC bought a new position in shares of Harrow during the third quarter valued at about $29,000. nVerses Capital LLC purchased a new stake in shares of Harrow during the second quarter worth about $33,000. Finally, Allspring Global Investments Holdings LLC grew its stake in shares of Harrow by 2,730.7% in the second quarter. Allspring Global Investments Holdings LLC now owns 2,123 shares of the company’s stock worth $44,000 after purchasing an additional 2,048 shares during the last quarter. Institutional investors own 72.76% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have commented on HROW shares. Craig Hallum upped their price target on Harrow from $45.00 to $65.00 and gave the company a “buy” rating in a research report on Friday, October 4th. Lake Street Capital upped their target price on Harrow from $45.00 to $55.00 and gave the company a “buy” rating in a report on Friday, October 4th. Finally, B. Riley dropped their price target on Harrow from $73.00 to $69.00 and set a “buy” rating for the company in a research note on Wednesday, December 4th.

Harrow Price Performance

Shares of NASDAQ HROW opened at $34.08 on Thursday. Harrow, Inc. has a 1 year low of $9.13 and a 1 year high of $59.23. The stock has a market capitalization of $1.21 billion, a P/E ratio of -36.26 and a beta of 0.69. The company’s 50-day moving average is $45.53 and its 200 day moving average is $36.43. The company has a debt-to-equity ratio of 3.23, a current ratio of 1.55 and a quick ratio of 1.44.

Harrow Company Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.